Revised the cumulative earnings guidance for the second quarter of the fiscal year ending March 2027. Net sales have been revised upward to 45,500 million yen (up 700 million yen, +1.6% vs. previous forecast), operating income revised upward to 1,600 million yen (up 1,100 million yen, +70.6%), ordinary income revised upward to 2,900 million yen (up 1,200 million yen, +70.6%), while interim net income attributable to owners of parent is revised to 5,100 million yen (down 2,300 million yen, -34.5%). The revisions reflect growth in new drugs and contributions from the information services business. The full-year outlook will be announced at the second quarter earnings announcement.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4547","jir_company_name":"Kissei Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-29","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4547-20261029-01.pdf","jir_short_summary":"Revised the cumulative earnings guidance for the second quarter of the fiscal year ending March 2027. Net sales have been revised upward to 45,500 million yen (up 700 million yen, +1.6% vs. previous forecast), operating income revised upward to 1,600 million yen (up 1,100 million yen, +70.6%), ordinary income revised upward to 2,900 million yen (up 1,200 million yen, +70.6%), while interim net income attributable to owners of parent is revised to 5,100 million yen (down 2,300 million yen, -34.5%). The revisions reflect growth in new drugs and contributions from the information services business. The full-year outlook will be announced at the second quarter earnings announcement.","jir_summary":"### Overview of Revision to Earnings Guidance\nThis document reports a revision to the earnings guidance for the cumulative second quarter of the fiscal year ending March 2027. Net sales are expected to exceed the previous forecast due to growth in new products and businesses, and operating income and ordinary income are raised based on increased gross profit and cost efficiency. Conversely, interim net income is reduced due to a forecasted extraordinary loss related to Tabneus-related assets.\n\n### Outlook and Points to Note\nThe full-year earnings guidance will be announced at the second quarter financial results release. Factors that may affect the full-year outlook include foreign exchange information, sales trends of new drugs and therapeutics, expansion of co-promotion expenses, and contributions from the information services business. Caution is required due to uncertainties such as administrative procedures and market trends that may affect realization.","jir_financial_highlights":"Net Sales: 45,500 million yen (vs. previous forecast +700 million yen \/ +1.6%)\nOperating Income: 1,600 million yen (vs. previous forecast +1,100 million yen \/ +70.6%)\nOrdinary Income: 2,900 million yen (vs. previous forecast +1,200 million yen \/ +70.6%)\nInterim Net Income Attributable to Owners of Parent: 5,100 million yen (vs. previous forecast -2,300 million yen \/ -34.5%)\nInterim Net Income per Share: 122.19 yen (vs. previous forecast -54.73 yen \/ -31.1%)","jir_category":"","jir_hashtags":"#KisseiPharmaceutical #RevisionToEarningsGuidance","jir_key_figures":"Net Sales: 45,500 million yen\nOperating Income: 1,600 million yen\nOrdinary Income: 2,900 million yen\nInterim Net Income Attributable to Owners of Parent: 5,100 million yen","jir_meta_title":"Kissei Pharmaceutical Co., Ltd. \u2014 Revision to Earnings Guidance\uff5cQ2 Cumulative FY2027","jir_meta_description":"Revised the cumulative earnings guidance for Q2 of FY2027: Net sales 45,500 million yen, operating income 1,600 million yen, ordinary income 2,900 million yen, interim net income attributable to owners of parent 5,100 million yen. The full-year outlook will be disclosed on November 4.","jir_og_title":"Kissei Pharmaceutical Co., Ltd. \u2014 Revision to Earnings Guidance\uff5cQ2 Cumulative FY2027","jir_og_description":"Earnings guidance has been raised due to growth in new drugs and contributions from information services. However, interim net income is expected to decrease due to an extraordinary loss.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8930,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"earnings_guidance","footnotes":""},"sector":[],"importance":[],"class_list":["post-136608","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n